title: The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents.
abstract: Neuronal nicotinic acetylcholine receptors (NAChRs) are pentameric ligand-gated ion channel receptors which exist as different functional subunit combinations which apparently subserve different physiological functions as indicated by molecular biological and pharmacological techniques. It is possible to design and synthesize novel compounds that have greater selective affinities and efficacies than nicotine for different NAChRs, which should translate into different behavioral profiles and therapeutic potentials. Examples of NAChR agonists studied are nicotine, SIB-1508Y, SIB-1553A and epibatidine. These compounds have different degrees of selectivity for human recombinant NAChRs, different neurotransmitter release profiles in vitro and in vivo and differential behavioral profiles. Preclinical studies suggest that SIB-1508Y is a candidate for the treatment of the motor and cognitive deficits of Parkinson's disease, whereas SIB-1553A appears to have potential as a candidate for the treatment of Alzheimer's disease. Epibatidine has a strong analgesic profile, however the ratio between pharmacological activity and undesirable effects is so low that it is difficult to envisage the use of this compound therapeutically. Nicotine has a broad profile of pharmacological activity, for instance demonstrating activity in models for cognition and analgesia. As for epibatidine, the adverse effects of nicotine severely limits its therapeutic use in humans. The discovery of subtype-selective NAChR agonists such as SIB-1508Y and SIB-1553A provides a new class of neuropsychopharmacological agents with better therapeutic ratios than nonspecific agents such as nicotine.
authors.affiliation: SIBIA Neurosciences Inc., La Jolla, CA 92037, USA.
authors.forename: G K
authors.initials: GK
authors.lastname: Lloyd
authors.forename: F
authors.initials: F
authors.lastname: Menzaghi
authors.forename: B
authors.initials: B
authors.lastname: Bontempi
authors.forename: C
authors.initials: C
authors.lastname: Suto
authors.forename: R
authors.initials: R
authors.lastname: Siegel
authors.forename: M
authors.initials: M
authors.lastname: Akong
authors.forename: K
authors.initials: K
authors.lastname: Stauderman
authors.forename: G
authors.initials: G
authors.lastname: Velicelebi
authors.forename: E
authors.initials: E
authors.lastname: Johnson
authors.forename: M M
authors.initials: MM
authors.lastname: Harpold
authors.forename: T S
authors.initials: TS
authors.lastname: Rao
authors.forename: A I
authors.initials: AI
authors.lastname: Sacaan
authors.forename: L E
authors.initials: LE
authors.lastname: Chavez-Noriega
authors.forename: M S
authors.initials: MS
authors.lastname: Washburn
authors.forename: J M
authors.initials: JM
authors.lastname: Vernier
authors.forename: N D
authors.initials: ND
authors.lastname: Cosford
authors.forename: L A
authors.initials: LA
authors.lastname: McDonald
mesh_terms: D000818:Animals; D006801:Humans; D009474:Neurons / Q000187:drug effects / Q000648:ultrastructure*; D018722:Nicotinic Agonists / Q000494:pharmacology*; D011978:Receptors, Nicotinic / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D013379:Substrate Specificity
chemical_list: D018722:Nicotinic Agonists; D011978:Receptors, Nicotinic